Crane NXT (CXT) Q3 2026 Earnings Call Transcript

Crane NXT reported Q3 sales of $497.1 million, up 11.7% year over year, while organic sales grew 1.1%; adjusted EPS was flat at $1.28 and adjusted EBITDA margin fell 190 bps to 25.6%, partly reflecting Antares Vision acquisition dilution. Strong SAT performance, with 7.2% organic growth and backlog up 8% to $481.6 million, helped lift the midpoint of full-year adjusted EPS guidance to $4.37, while total sales growth guidance was lowered to approximately 14% amid softness in CPI hardware and slower Antares Vision project conversion. Adjusted free cash flow rose 15% to $98 million, and management expects net leverage to decline from 2.5x to approximately 2.3x by year-end; the company also declared a quarterly dividend of $0.18 per share.

Analysis

The key debate is earnings quality, not headline growth: acquired revenue is masking weak DTT organic demand, while the EPS midpoint rose despite a lower sales outlook. That makes productivity, mix and lower borrowing costs critical offsets; any shortfall in those levers could expose earnings to more downside than the revised sales guide implies. The acquisition-driven margin dilution also means reported growth may not translate into near-term multiple support until Antares demonstrates conversion and accretion.

SAT is the stronger asset, but its backlog is a delivery schedule and capacity challenge, not a guarantee of near-term upside. Orders extending into 2028 support visibility, while accelerated micro-optics capex and hiring create execution risk before incremental capacity contributes. A favorable mix toward higher-denomination U.S. notes could help, but the separate CPI device-refresh opportunity is gated by the timing and adoption of redesigned currency; it should not be capitalized as an imminent recovery in hardware.

Over 1–3 months, watch Antares project installations moving into Q1, retailer refresh timing, and whether free cash flow delivers targeted deleveraging. Over 6–18 months, SAT capacity ramp and CPI service expansion could improve the growth mix; conversely, persistent hardware weakness or further life-sciences delays would leave CXT more acquisition-dependent. The contrarian risk is treating backlog and long contracts as equivalent to smooth earnings: customer-controlled installation windows and capacity additions can shift both revenue and cash conversion.

Key Decisions for Investors

• Avoid chasing the earnings reaction; consider scaling into CXT only on weakness if SAT backlog conversion and the year-end leverage target remain intact. The setup is a medium-term execution long, not a clean near-term organic-growth breakout.
• Use the Q4 call as a checkpoint: verify Antares’ delayed projects actually install in Q1, organic DTT trends improve, and acquired-business margin dilution narrows. If timing slips again or DTT organic declines deepen, reduce exposure rather than relying on management’s funnel commentary.
• Treat the U.S. currency redesign as a conditional CPI catalyst, not part of the base case until launch timing and customer refresh orders are evident. Track CPI hardware orders separately from service growth; stable backlog alone does not confirm a device-replacement cycle.
• Falsifiers for the constructive thesis: failure to reach the stated year-end leverage objective, SAT backlog conversion/capacity delays, or full-year EBITDA margin falling below guidance. No compelling pair trade is evident from the supplied information.